Having the most up-to-date information on potential reimbursement and drug costs allows providers to educate patients and create payment plans that fits their needs, said Rhett Wilkerson, BA, director of patient financial services dedicated to American Oncology Network at Florida Cancer Specialists & Research Institute.
Having the most up-to-date information on potential reimbursement and drug costs allows providers to educate patients and create payment plans that fits their needs, said Rhett Wilkerson, BA, director of patient financial services dedicated to American Oncology Network at Florida Cancer Specialists & Research Institute.
Transcript
Are practices making it a priority to include financial counseling for patients within their revenue cycle management?
Yeah, practices are making it a huge priority. As important as it is for the patient to find out what treatment they’re going to be having, it’s equally as important that they find out how they’re going to be paying for that treatment. The earlier you can give them that information, the better prepared they’ll be to either make that payment or find some sort of assistance that would help them
How important is this as drug costs continue to increase and patients are held accountable for more cost-sharing?
That’s the main driver of 1 of the reasons why it’s so important. We have to make sure that we’re covering our drug costs, so if someone’s not able to pay, how we put together that payment plan could very well be determined on what that drug cost looks like. So, it’s important for us to always have the most up-to-date reimbursement and drug costs so we can put together payment plans that fit for folks if they’re not able to make full payments at time of service.
The Challenge of Addressing Drug Spend to Drive Down Total Cost of Care in EOM
October 27th 2024Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More